drugset / Trial / NCT05123131
Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma
Phase 2
Active not recruiting
54 enrolled
Cancer Trials Ireland
Dana-Farber Cancer Institute · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the stringent Complete Response (sCR) rate by the end of two cycles of induction treatment, defined as the proportion of patients who have achieved sCR, according to International Myeloma Working Group (IMWG) criteria, by the end of two cycles of induction treatment.
Timeline
- Start
- 2022-04-01
- Primary completion
- 2025-06-24
- Completion
- 2027-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |
| Subject | Dexamethasone | Small molecule | 20 mg | Intravenous |
| Subject | Isatuximab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |